Unfortunately, rapid weight loss can stress the body and disrupt the normal hair cycle, causing shedding. Nutritional deficiencies and hormonal shifts common during medical weight loss may worsen this effect
Both oral and injectable semaglutide share a similar adverse effect profile, with gastrointestinal symptoms representing the most common tolerability concerns
Sipping water with meals helps, but avoid drinking large amounts during meals as this can contribute to bloating and discomfort when your stomach empties slowly
long-term epidemiological data absent Metabolic effects potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies Endocrine disruption effects on other hormonal axes with chronic use not well-studied Regulatory & Competitive Sport Status FDA Position Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication: Investigational New Drug status available only for qualified research applications 2024 FDA compounding restrictions both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review Not approved for human use in any formulation or indication Warning letters issued to companies marketing peptides for human therapeutic use Compounding status uncertain as of 2024-2025, regulatory position on compounding pharmacy access remains in flux The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts
RESILIENT trial: bimagrumab in sIBM
Semaglutide Benefits Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been making waves in the world of weight management due to its impressive ability to promote weight loss
![Twister [SBLS-EN042] Ultra Rare Guardian](https://cdn.shopify.com/s/files/1/0581/0284/1476/products/c1787672-a5a3-5a29-863b-a958125a6fcc.png?v=1649189331)
